The UK is continuing to demonstrate competitive performance in its peer group (a sample of other countries within and outside the EU comparable to the UK) for Phase III trials, although trailing behind the US The UK follows closely behind Germany, Spain and Canada in 2016. The bigger trend this year is the generalised decline in the number of trial initiations for Phase III trials. This may be temporary, or it may reflect a change in clinical development strategies to better fit the technologies explored and/or to support efficiencies in development overall. Such a conclusion requires a longer time series to average across.
Only commercial trials related to pharmaceutical drug development and molecular/biological entities were included. Collaborative trials were only included if one or more partners were a commercial organisation and all therapeutic areas were included in this analysis.